Fig. 4: JQ1 and Bortezomib induce synergistic effect through upregulation of GADD45. | Cell Death & Disease

Fig. 4: JQ1 and Bortezomib induce synergistic effect through upregulation of GADD45.

From: Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions

Fig. 4: JQ1 and Bortezomib induce synergistic effect through upregulation of GADD45.The alternative text for this image may have been generated using AI.

a mRNA alteration of GADD45 in HCT116 and LoVo cells treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 24 h. b LoVo and HCT116 cells were transfected with GADD45A/B/G siRNA for 2 days, then cells were treated with indicated compounds for another 72 h. Cell viability was measured by CCK8. c Xenograft growth curves of shGADD45B/G HCT116 stable cells treated with vehicle (control), JQ1, Bortezomib, or JQ1+Bortezomib for 18 days. d mRNA alteration of c-myc in HCT116 and LoVo treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 24 h. e Western blot analysis of HCT116 and LoVo cells treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 24 h. f Immunohistochemical staining of c-myc, GADD45A/B/G in xenograft tumor sections of HCT116 cells. Bar, 100 μm

Back to article page